triphenylphosphonium [α-(1-adamantanylacetyl)-α-ethoxycarbonyl]methylide | 455333-75-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: triphenylphosphonium [α-(1-adamantanylacetyl)-α-ethoxycarbonyl]methylide
• CAS: 455333-75-2
• 化学式: C₃₄H₃₇O₃P
• 分子量: 524.64
• InChiKey: LHPPRPHNBFYDTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.89
• 重原子数：
  38.0
• 可旋转键数：
  8.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.37
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  triphenylphosphonium [α-(1-adamantanylacetyl)-α-ethoxycarbonyl]methylide 在 Oxone 、 ammonium acetate 、 溶剂黄146 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 ethyl 5-(1-adamantylmethyl)-2-phenyl-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  Scaffold Hopping with Molecular Field Points:  Identification of a Cholecystokinin-2 (CCK₂) Receptor Pharmacophore and Its Use in the Design of a Prototypical Series of Pyrrole- and Imidazole-Based CCK₂ Antagonists

  摘要：

  A new molecular modeling approach has been used to derive a pharmacophore of the potent and selective cholecystokinin-2 (CCK2) receptor antagonist 5 (JB93182), based on features shared with two related series. The technique uses "field points" as simple and effective descriptions of the electrostatic and van der Waals maxima and minima surrounding a molecule equipped with XED (extended electron distribution) charges. Problems associated with the high levels of biliary elimination of 5 in vivo required us to design a compound with significantly lower molecular weight without sacrificing its nanomolar levels of in vitro activity. Two new series of compounds were designed to mimic the arrangement of field points present in the pharmacophore rather than its structural elements. In a formal sense, two of the three amides in 5 were replaced with either a simple pyrrole or imidazole, while some features thought to be essential for the high levels of in vitro activity of the parent compounds were retained and others deleted. These compounds maintained activity and selectivity for this receptor over CCK1. In addition, the reduction in molecular weight coupled with lower polarities greatly reduced levels of biliary elimination associated with 5. This makes them good lead compounds for development of drug candidates whose structures are not obviously related to those of the parents and represents the first example of scaffold hopping using molecular field points.

  DOI：

  10.1021/jm049069y
• 作为产物：
  描述：

  1-金刚烷乙酸 、 乙氧甲酰基亚甲基三苯基膦 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 triphenylphosphonium [α-(1-adamantanylacetyl)-α-ethoxycarbonyl]methylide
  参考文献：
  名称：

  优化一系列新型的2,4,5-三取代的咪唑类作为有效的胆囊收缩素2（CCK2）拮抗剂的体外和体内特性。

  摘要：

  新型的2,4,5-三取代的咪唑基胆囊收缩素2（CCK（2））受体拮抗剂的结构的系统优化提供了具有纳摩尔受体亲和力的类似物。这些化合物的效价现在与基于双环杂芳族化合物5（JB93182）和6（JB95008）的效价相当，后者使用基于场点的分子建模方法设计了初始实例。通过抑制五肽胃泌素刺激的清醒犬的酸分泌可以判断，它们也具有口服活性，这与基于双环杂芳香族化合物的化合物（由于胆道消除而无效）相反。通过用醚氧置换特定的亚甲基来增加亲水性，如3-{[5-（金刚烷-1-基氧甲基）-2-环己基-1H-咪唑-4-羰基]氨基}苯甲酸中的苯甲酸（53）一样，对受体亲和力的影响很小，但显着提高了口服药的效力。 。比较血浆药代动力学和对十二指肠内推注53和6后五肽胃泌素刺激的酸输出的抑制作用，表明53吸收良好，半衰期更长，并且不受早期系列的消除途径的影响。

  DOI：

  10.1021/jm0490686

文献信息

• ——
  作者：N. I. Miryan、S. D. Isaev、A. G. Yurchenko、I. V. Gulyaiko、T. Yu. Voinovskaya、Yu. V. Rassukana、N. V. Shchirova

  DOI：10.1023/a:1015501313852

  日期：——

  Sodium derivative of diethyl(3-amino-1-ethoxycarbonylpropane)phosphonic acid was obtained by reaction of triethyl phosphonoacetate with ethylene imine in the presence of sodium hydride. The compound obtained was brought into Horner-Emmons reaction with carbonyl derivatives of adamantane series to afford the corresponding unsaturated amino acids. From adamantanecarbonyl chlorides and triphenylphosphonium ethoxycarbonylmethylide new phosphorus acylylides that on thermolysis provide ethyl acetylenecarboxylates containing an adamantyl substituent were prepared.